Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +62

Edwards Lifesciences stock slips after Medicare TAVR decision as analysts reaffirm upside

AI-generated analysis

📉 Edwards Lifesciences shares dropped 2.8% to $84.31 intraday on September 11, 2026, after opening at $87.51 as investors digested the new Medicare TAVR coverage rules.

✅ The company reaffirmed full-year 2026 guidance with projected sales growth of 10-11% and EPS between $2.95 and $3.05.

📈 Recent quarterly results beat expectations, with EPS of $0.78 vs. consensus of $0.74 and revenue of $1.74 billion vs. $1.70 billion.

🔍 Analysts at BTIG and Citi maintain Buy ratings with price targets set at $110, implying roughly 26-30% upside from current levels.

📊 The stock trades at a premium valuation with a P/E ratio of 51.54 and a market capitalization of approximately $50 billion.

🏥 CMS updated national coverage determination for TAVR, removing prior evidence requirements for symptomatic severe cases and extending access to certain asymptomatic patients.

📉 The stock has underperformed the S&P 500 year-to-date, posting a 1.06% return compared to the index's 12.0% gain.

⚖️ Canaccord reiterated a Hold rating citing a premium valuation that tempers optimism despite favorable regulatory outcomes.

📉 Quiver Quantitative attributes the share price decline to a muted 'sell-the-news' response rather than negative company-specific data.

🔮 GuruFocus calculates the stock trades about 9% below its GF Value estimate of $95.33, suggesting moderate undervaluation.

Bullish Signals
  • Edwards Lifesciences reaffirmed full-year 2026 guidance with projected sales growth of 10-11% and EPS between $2.95 and $3.05.
  • The company delivered a quarterly earnings beat, reporting EPS of $0.78 versus the analyst consensus of $0.74.
  • Quarterly revenue reached $1.74 billion, exceeding expectations of $1.70 billion and growing 13.6% year over year.
  • Major analysts BTIG and Citi maintain Buy ratings with price targets of $110, indicating significant upside potential.
  • The updated Medicare TAVR coverage removes prior evidence development requirements for symptomatic severe aortic valve stenosis.
  • CMS extended TAVR coverage to certain asymptomatic severe cases under evidence development frameworks, broadening patient access.
  • The stock trades at approximately 9% below its GF Value estimate of $95.33, suggesting moderate undervaluation.
  • Consensus analyst sentiment is Moderate Buy with an average price target near $101, implying nearly 20% upside.
Risk Factors
  • Shares slipped 2.8% intraday to $84.31 as investors reacted to the new Medicare TAVR coverage update.
  • The stock has significantly lagged the broader market year-to-date, posting a 1.06% return versus the S&P 500's 12.0% gain.
  • Canaccord reiterated a Hold rating citing a premium valuation with a P/E ratio of 51.54 that may limit multiple expansion.
  • Investors are still calibrating the long-term impact of the Medicare update on hospital reimbursement levels and adoption rates.
  • Coverage rules for asymptomatic patients still involve evidence-development requirements, which could influence procedural volumes.
Full Analysis
Edwards Lifesciences stock slipped approximately 2.8% to trade around $84.31 on September 11, 2026, following a Medicare coverage update for transcatheter aortic valve replacement (TAVR) procedures. Despite the immediate price dip, analysts from major firms like BTIG and Citi reaffirmed their Buy ratings with price targets of $110, signaling significant upside potential relative to current trading levels. The company reaffirmed its full-year 2026 guidance, projecting sales growth between 10% and 11% and earnings per share (EPS) ranging from $2.95 to $3.05. This positive outlook follows a recent quarterly report where Edwards Lifesciences beat market expectations, reporting EPS of $0.78 against a consensus of $0.74 and revenue of $1.74 billion versus an expected $1.70 billion. Analyst sentiment remains broadly positive, with 17 analysts rating the stock as Buy compared to six Hold ratings, resulting in a consensus Moderate Buy rating and an average price target near $101. However, some investors view the current valuation as a counterweight to growth, noting a premium P/E ratio of 51.54 that may limit multiple expansion even if sales continue to grow robustly. The updated Medicare policy removes prior evidence development requirements for symptomatic severe aortic valve stenosis and extends coverage to certain asymptomatic cases, broadening access to the therapy. While this reduces regulatory uncertainty, investors are still calibrating the long-term impact on adoption rates and procedural volumes, with some viewing the stock's decline as a 'sell-the-news' reaction rather than a reflection of negative fundamentals.